Colleges get free mental health blueprints—no strings attached

What it does

This bill directs the U.S. Department of Education, working with the Department of Health and Human Services, to develop evidence-based model mental health and suicide prevention plans for colleges and universities, update them every 5 years, and provide technical assistance to schools that want to adopt them. The bill explicitly states it creates no new legal requirements—participation is voluntary.

Why we flagged it

The bill's sole function is to direct federal agencies to create and share voluntary mental health planning resources with colleges. It is a straightforward public health coordination measure with no regulatory teeth or private benefit.

What the text implies

• Voluntary adoption may create de facto pressure on institutions to implement plans to avoid reputational risk or liability concerns, even though the bill explicitly disclaims legal requirements.
• Model plans developed by federal agencies may influence institutional liability exposure if a school deviates from them and a suicide occurs—creating indirect incentive to comply despite voluntary language.
• Pharmaceutical companies mapped to this bill (BMY, PFE, JNJ, DVA) may benefit indirectly if model plans recommend or normalize psychiatric medication as part of campus mental health infrastructure, though the bill text does not specify treatment modalities.

Who it affects

College students and their families benefit from access to evidence-based suicide prevention frameworks and technical support at no cost or mandate. The voluntary nature protects institutional autonomy while offering a public health resource. No identifiable harm to ordinary citizens.

Who stands to gain

• Pharmaceutical companies (if model plans recommend medication-based interventions)
• Mental health service providers and consultants (technical assistance contracts)
• Nonprofit mental health organizations (potential collaboration partners)

Named in the bill

U.S. Department of Education, U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA), Institutions of higher education, Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce, House Committee on Education and Workforce, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)

Where it stands

4 cosponsors: 2 Democrats, 2 Republicans.

• Jun 18, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 18, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $690,000 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Richard Blumenthal, the sponsor, reported $111,550 in PAC receipts in the 2026 cycle.

• National Education Association — $670,000 on 1 filing
• American College Health Association — $10,000 on 1 filing
• Association on Higher Education and Disability (ahead) — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.